-
1
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
-
2
-
-
11144354274
-
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
-
Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.
-
(2004)
Blood
, vol.103
, pp. 2873-2878
-
-
Kantarjian, H.1
Talpaz, M.2
O'Brien, S.3
-
3
-
-
16844372957
-
Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials
-
abstract
-
Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104:11a. abstract.
-
(2004)
Blood
, vol.104
-
-
Silver, R.T.1
Talpaz, M.2
Sawyers, C.L.3
-
4
-
-
9444289883
-
Combination of intensive chemotherapy with imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
-
Towartari M, Yanada M, Usui N, et al. Combination of intensive chemotherapy with imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507-12.
-
(2004)
Blood
, vol.104
, pp. 3507-3512
-
-
Towartari, M.1
Yanada, M.2
Usui, N.3
-
5
-
-
0037105560
-
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
-
Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
-
(2002)
Blood
, vol.100
, pp. 1965-1971
-
-
Ottmann, O.G.1
Druker, B.J.2
Sawyers, C.L.3
-
6
-
-
4043137682
-
A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia
-
abstract
-
Ottmann OG, Wassmann B, Goekbuget N, et al. A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia. Blood 2003;102:226a. abstract.
-
(2003)
Blood
, vol.102
-
-
Ottmann, O.G.1
Wassmann, B.2
Goekbuget, N.3
-
7
-
-
2942567555
-
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
-
Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407.
-
(2004)
Blood
, vol.103
, pp. 4396-4407
-
-
Thomas, D.A.1
Faderl, S.2
Cortes, J.3
-
8
-
-
24644464172
-
AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
-
Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005;104:1230-6.
-
(2005)
Cancer
, vol.104
, pp. 1230-1236
-
-
Verstovsek, S.1
Golemovic, M.2
Kantarjian, H.3
-
9
-
-
24644435728
-
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
-
Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005;11:4941-7.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4941-4947
-
-
Golemovic, M.1
Verstovsek, S.2
Giles, F.3
-
10
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Erratum, Cancer Cell 2005;7:399
-
Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-4. [Erratum, Cancer Cell 2005;7:399.]
-
(2005)
Cancer Cell
, vol.7
, pp. 129-134
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
11
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
-
(2005)
Cancer Res
, vol.65
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
-
12
-
-
33745089491
-
AMN107: Inhibitory profile against wild-type and mutant forms of the BCR-ABL tyrosine kinase
-
Anaheim, Calif., April 16-20, abstract
-
Manley P, von Bubnoff N, Duyster J, et al. AMN107: inhibitory profile against wild-type and mutant forms of the BCR-ABL tyrosine kinase. Presented at the 96th annual meeting of the American Association for Cancer Research, Anaheim, Calif., April 16-20, 2005. abstract.
-
(2005)
96th Annual Meeting of the American Association for Cancer Research
-
-
Manley, P.1
Von Bubnoff, N.2
Duyster, J.3
-
14
-
-
0023841366
-
Characteristics of accelerated disease in chronic myelogenous leukemia
-
Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6.
-
(1988)
Cancer
, vol.61
, pp. 1441-1446
-
-
Kantarjian, H.M.1
Dixon, D.2
Keating, M.J.3
-
15
-
-
0023634256
-
Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients
-
Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 1987;83:445-54.
-
(1987)
Am J Med
, vol.83
, pp. 445-454
-
-
Kantarjian, H.M.1
Keating, M.J.2
Talpaz, M.3
-
16
-
-
0037186915
-
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
-
Erratum, N Engl J Med 2002;346:1923
-
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. [Erratum, N Engl J Med 2002;346:1923.]
-
(2002)
N Engl J Med
, vol.346
, pp. 645-652
-
-
Kantarjian, H.1
Sawyers, C.2
Hochhaus, A.3
-
17
-
-
0012906888
-
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
-
Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-800.
-
(2003)
Blood
, vol.101
, pp. 3794-3800
-
-
Cortes, J.E.1
Talpaz, M.2
Giles, F.3
-
19
-
-
0037092980
-
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
-
Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
-
(2002)
Blood
, vol.99
, pp. 3547-3553
-
-
Kantarjian, H.M.1
Cortes, J.2
O'Brien, S.3
-
20
-
-
20944442975
-
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
-
Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3425-3432
-
-
Cortes, J.1
Talpaz, M.2
O'Brien, S.3
-
21
-
-
11344291101
-
U.S. Food and Drug Administration Drug Approval Summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval
-
Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-9.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 12-19
-
-
Cohen, M.H.1
Johnson, J.R.2
Pazdur, R.3
-
22
-
-
0028867826
-
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
-
Bosma P, Chowdhury J, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
-
(1995)
N Engl J Med
, vol.333
, pp. 1171-1175
-
-
Bosma, P.1
Chowdhury, J.2
Bakker, C.3
-
23
-
-
0038518619
-
Practical management of patients with chronic myeloid leukemia receiving imatinib
-
Deininger M, O'Brien S, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:4255-6.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4255-4256
-
-
Deininger, M.1
O'Brien, S.2
Ford, J.M.3
Druker, B.J.4
-
24
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
-
(2006)
N Engl J Med
, vol.354
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
|